Roberts Glore & Co. Inc. IL Makes New $648,000 Investment in Biogen Inc. $BIIB

Roberts Glore & Co. Inc. IL bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,001 shares of the biotechnology company’s stock, valued at approximately $648,000.

Several other large investors have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Biogen in the second quarter valued at $3,453,878,000. Primecap Management Co. CA acquired a new position in Biogen during the 2nd quarter worth about $3,274,304,000. Norges Bank bought a new stake in Biogen during the 4th quarter worth about $464,408,000. Boston Partners acquired a new stake in Biogen in the 4th quarter valued at about $302,815,000. Finally, Legal & General Group Plc acquired a new stake in Biogen in the 2nd quarter valued at about $322,640,000. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB stock opened at $220.77 on Wednesday. Biogen Inc. has a twelve month low of $131.52 and a twelve month high of $222.85. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $32.62 billion, a P/E ratio of 39.07, a price-to-earnings-growth ratio of 6.80 and a beta of 0.17. The business’s fifty day moving average is $206.42 and its 200-day moving average is $195.12.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts forecast that Biogen Inc. will post 12.39 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on BIIB shares. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Sanford C. Bernstein cut their price target on Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, HSBC reiterated a “reduce” rating and issued a $157.00 price objective on shares of Biogen in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $227.79.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ?4 homozygotes, could constrain uptake and increase implementation costs.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.